Aktuellt
SENASTE
On 9 December, Curasight announced that results from an investigator sponsored trial with its uTRACE technology had been published online in the Journal of Nuclear Medicine. The data supports the use of uTRACE as a prognostic for planning of therapy and follow-up in head and neck cancer patients. We do not assign any value to this indication for uTRACE right now, but could decide to do this if Curasight moves forward with this indication for uTRACE.
LÄS MER
